Navigation Links
Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal
Date:12/13/2010

e by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency.  Generex claims the protection of the sa
'/>"/>
SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
9. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
10. Generex Provides Clarification for Special Meeting Voting
11. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015 Rock Creek Pharmaceuticals, Inc., ... on chronic inflammatory disease and neurologic disorders, announced today ... with anatabine citrate, the Company,s lead compound. Results from ... anatabine citrate can significantly inhibit the activation of inflammatory ... is developing this compound in a Phase 1 clinical ...
(Date:7/1/2015)... SAN FRANCISCO , July 1, 2015 ... a new study Stationary Oxygen Concentrators Market ... markets are poised to achieve continuing growth as the ... develop COPD and other respiratory conditions where oxygen is ... a dramatic manner. Portable devices have become affordable and ...
(Date:7/1/2015)... DIEGO , July 1, 2015 OncoSec Medical ... intratumoral cancer immunotherapies, today announced that CEO and President ... celebration of the Company,s listing to The Nasdaq Stock Market ... Nasdaq MarketSite in New York City . ... employees, investors, and stakeholders, we are honored to open the ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 3Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 4OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell 2OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell 3
... releases of Elekta,s XiO® treatment planning system and Focal ... and deliver radiation therapy plans more efficiently. ... Therapy (IMRT) segmentation algorithm, fluence map smoothing and DICOM ... for contouring, enabling clinicians to contour anatomy faster and ...
... the vaccines division of Sanofi (EURONEXT: SAN and NYSE: ... 2011-2012 Fluzone® Influenza Virus Vaccine in the U.S. This shipment ... influenza vaccine the company plans to deliver to the U.S. ... producer of influenza vaccine in the U.S., supplying more than ...
Cached Medicine Technology:Latest Releases of Elekta's XiO Planning and Focal Contouring Systems Designed to Increase Efficiency in Planning Therapy for Patients with Cancer 2Sanofi Pasteur Starts Shipping Influenza Vaccine for the 2011-2012 Season 2Sanofi Pasteur Starts Shipping Influenza Vaccine for the 2011-2012 Season 3Sanofi Pasteur Starts Shipping Influenza Vaccine for the 2011-2012 Season 4Sanofi Pasteur Starts Shipping Influenza Vaccine for the 2011-2012 Season 5Sanofi Pasteur Starts Shipping Influenza Vaccine for the 2011-2012 Season 6
(Date:7/1/2015)... ... 01, 2015 , ... “Well-meaning social policy often has unintended ... FIU’s School of International and Public Affairs. , The researchers examined ... National Survey on Drug Use and Health, which is a nationally representative survey ...
(Date:7/1/2015)... Orange, NJ (PRWEB) , ... July 01, 2015 , ... Scoliosis is a disorder in ... the National Scoliosis Foundation, it affects 2 to 3 percent of the population, or an ... scoliosis most often develops in children between the ages of 10 and 15. Most types ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... delicatessen products, is helping families get ready for Independence Day celebrations with new ... these easy and versatile options are perfect for any summertime get together. , ...
(Date:7/1/2015)... Mesa, Arizona (PRWEB) , ... July 01, 2015 , ... ... recently opened a new office in the greater Phoenix area – their Mesa, ... the move to senior care with their purchase of the rights to the area ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... healthcare providers, has been retained to lead a national chief executive officer ... executive search firms in the healthcare industry, B. E. Smith has recently placed ...
Breaking Medicine News(10 mins):Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 4Health News:Boar’s Head Helps Craft a Delicious Independence Day 2Health News:Boar’s Head Helps Craft a Delicious Independence Day 3Health News:Amada Senior Care Expands to Greater Phoenix Area 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 3
... ... children,s products Yum-Yum D3 liquid, Yum-Yum GOS Syrup (prebiotic fiber syrup), Yum-Yum Zymes; and Brown ... show to be held at Sands Expo & Convention Center/The Venetian Resort Hotel Las Vegas, ... Los ...
... ... , ... 2009 -- Dr. Jan Linhart, a top-rated dentist with offices in Manhattan, claims that orthodontic work ... such as Invisalign and iBraces are extraordinarily effective at creating a beautiful ...
... , Verizon Business, Fully Managed Solution Provides Secure Foundation ... , PARIS, June 25 Invacare Corp., ... equipment, has chosen Verizon Business to deploy and manage ... Private IP solution effectively quadruples the bandwidth available to ...
... ... locum tenens physicians, Jackson & Coker has helped sponsor several "medical brigades" visiting Honduras ... ... 2009 -- Tapping the growing interest in medical volunteerism shown by many locum tenens ...
... 2009 -- Many parents worry about their child,s exposure to ... variety of personal care products, children,s toys, and medical devices. ... been associated with negative changes in endocrine function. A ... of Pediatrics examines the possibility that in utero phthalate ...
... June 24 Siemens Healthcare ( ... Miller, Chief Executive Officer (CEO) for the Workflow & Solutions ... Energy and Commerce, U.S. House of Representatives on the need ... http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ) , ...
Cached Medicine News:Health News:Jarrow Formulas, Inc. to Unveil Children's Natural Health Products at Upcoming Natural MarketPlace 2009 Show in Las Vegas 2Health News:Jarrow Formulas, Inc. to Unveil Children's Natural Health Products at Upcoming Natural MarketPlace 2009 Show in Las Vegas 3Health News:Top Dentist Issues Opinion on Health Benefits of Cutting-Edge Orthodontics 2Health News:Verizon Private IP Quadruples Network Capacity for Invacare's European Operations 2Health News:Verizon Private IP Quadruples Network Capacity for Invacare's European Operations 3Health News:Jackson & Coker Sponsors Medical Missions 2Health News:Jackson & Coker Sponsors Medical Missions 3Health News:Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 2Health News:Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 3
... Cardiac troponin I (cTnI) has been useful ... to Emergency Departments (ED) with chest pain. ... diagnosed when blood levels of sensitive and ... MB isoenzyme of creatine kinase (CK-MB), and ...
... Aio! 2nd generation cardiac troponin ... sensitive immunoassay providing quantitative results ... less than 18 minutes. The ... unique combination of antibodies that ...
... high-throughput immunoassay system built around the many ... the important addition of Logic Driven Incubation ... designed for optimal performance with the fastest ... assays such as the cardiac biomarkers and ...
The Acute Care myoglobin method is an in vitro diagnostic test for the measurement of myoglobin in heparinized whole blood /plasma. Myoglobin measurements can be used as an aid in diagnosing myocardi...
Medicine Products: